5月20日,三生制药(01530.HK)宣布与辉瑞达成一项总额高达60.5亿美元的授权协议,将其自主研发的PD-1/VEGF双特异性抗体SSGJ-707的全球(除中国内地)开发、生产和商业化权益独家授予辉瑞,同时保留该产品在中国内地的权益。 国产双抗出海首付款记录再次刷新 根据协议,三生制药及沈阳三生将保留SSGJ-707在中国内地的开发、生产、商业化权利。基于届时商定的财务条款,三生制药将授予...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.